Ruxolitinib data positive for efficacy, safety
Ruxolitinib met primary and secondary endpoints in the phase 3 TRueE-AD1 and TRuE-AD2 studies, underscoring the idea that the disruption of multiple cytokine networks simultaneously is a promising treatment approach.
 
ADVERTISEMENT
In search of a better way to assess itch
Researchers evaluating several itch assessment tools say there is a need for a better way. Studies comparing the validity and reliability of itch measurement scales are lacking, say researchers who examined several available assessment tools.